Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Angelman Syndrome
- Main trialPhase 3
- “Purpose of the study is to evaluate the efficacy and safety of intrathecally administered rugonersen in pediatric and adult participants with Angelman syndrome.”In the company’s words, NCT07605429 on ClinicalTrials.gov
Other drugs for Angelman Syndrome
- ObudanersenIonis Pharmaceuticals, Inc. · Phase 3
Coming up1
- Mar 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Mar 2029 | BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026